Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TIMP metallopeptidase inhibitor 3 is an extracellular protein encoded by the *TIMP3* gene. It belongs to the tissue inhibitors of metalloproteinases family and functions primarily as an endogenous regulator that inhibits various matrix metalloproteinases involved in extracellular matrix degradation. The protein is enriched in placenta and fat tissues and localizes within the extracellular space. Its expression can be induced by mitogenic stimulation. Mutations in *TIMP3* are associated with Sorsby fundus dystrophy, an autosomal dominant disorder affecting vision. The protein exists both unglycosylated (~24 kDa) and glycosylated (~29 kDa) forms with inhibitory activity against several MMPs including interstitial collagenase, stromelysin-1, gelatinase A, and gelatinase B[1][2][6].
No drugs are currently known to directly target or modulate TIMP metallopeptidase inhibitor 3 as a primary mechanism; however, its inhibition or upregulation may be influenced by indirect mechanisms in disease contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TIMP metallopeptidase inhibitor 3 (TIMP-3).